HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells

INTRODUCTION: Although the mechanistic target of rapamycin (mTOR) might be a promising molecular target to treat advanced bladder cancer, resistance develops under chronic exposure to an mTOR inhibitor (everolimus, temsirolimus). Based on earlier studies, we proposed that histone deacetylase (HDAC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Juengel, Eva, Najafi, Ramin, Rutz, Jochen, Maxeiner, Sebastian, Makarevic, Jasmina, Roos, Frederik, Tsaur, Igor, Haferkamp, Axel, Blaheta, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746361/
https://www.ncbi.nlm.nih.gov/pubmed/29299126
http://dx.doi.org/10.18632/oncotarget.22454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746361/
https://www.ncbi.nlm.nih.gov/pubmed/29299126
http://dx.doi.org/10.18632/oncotarget.22454

Ejemplares similares